Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody

B-cell maturation antigen (BCMA) is an ideal target in multiple myeloma (MM) due to highly specific expression in malignant plasma cells. BCMA-directed therapies including antibody drug conjugates, chimeric antigen receptor-T cells and bispecific antibodies (BsAbs) have shown high response rates in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2023-06, Vol.37 (6), p.1349-1360
Hauptverfasser:	Raab, Marc S, Cohen, Yael C, Schjesvold, Fredrik, Aardalen, Kimberly, Oka, Adwait, Spencer, Andrew, Wermke, Martin, Souza, Anita D, Kaufman, Jonathan L, Cafro, Anna Maria, Ocio, Enrique M, Doki, Noriko, Henson, Kristin, Trabucco, Gina, Carrion, Ana, Bender, Florent C, Juif, Pierre-Eric, Fessehatsion, Adonai, Fan, Liqiong, Stonehouse, Jeffrey P, Blankenship, John W, Granda, Brian, De Vita, Serena, Lu, Haihui
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies Antibodies, Bispecific - therapeutic use Antigens B-Cell Maturation Antigen Bispecific antibodies CD3 antigen Cell activation Chimeric antigen receptors Dosage Drug dosages Humans Immunoconjugates - therapeutic use Immunotherapy, Adoptive Lymphocytes Lymphocytes B Lymphocytes T Macaca fascicularis - metabolism Multiple myeloma Multiple Myeloma - pathology Plasma cells Response rates
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!